Schellenberg Wittmer acted as Swiss counsel to SPRIM Global Investments (SGI), a leading health sciences venture capital firm, in its capital commitment of USD 4.5 million in favor of Spexis AG, a clinical-stage and biopharmaceutical company listed on the SIX Swiss Exchange, to enable initiation of ColiFin® Phase 3 study.
The commitment was structured as a mix of secured debt and subordinated debt mandatorily converting into equity.
The Schellenberg Wittmer team consisted of Tarek Houdrouge (overall lead), Jérémie Tenot (Banking & Finance) and Alexander Zundel (Corporate/M&A).
Copy linkLink copied
+41 22 707 8107
+41 22 707 8054
+41 22 707 8048
This site is protected by reCAPTCHA and the Google
Terms of Service apply.